Bright Green Corporation announced that it has signed an agreement with Dalsem Greenhouse Technologies BV for a $250 million construction project to expand the Company?s current research, production and extraction processing facility located in rural Grants, New Mexico. The proposed expansion will add 7 million square feet of manufacturing and production capabilities. The Dalsem Agreement provides that Dalsem will construct the additional facility to its specifications and build them in a modular fashion.

This expansion is a direct result of Bright Green obtaining the regulatory approvals for the production of Schedule I and II controlled substances from the DEA and the State of New MexicoBoard of Pharmacy. The expansion will facilitate the production and manufacturing required to process the active pharmaceutical ingredients (?API?) and to make generic prescription drugs, supporting Bright Green's Drugs Made in America initiative. The company is finalizing negotiations for the necessary services from the city, landowners' land parcels and the necessary state permitting for the construction and occupancy.